| Serial Number | 97915885 |
| Word Mark | ACUITAS THERAPEUTICS |
| Filing Date | Monday, May 1, 2023 |
| Status | 680 - APPROVED FOR PUBLICATION |
| Status Date | Wednesday, June 24, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| NOT AVAILABLE | "THERAPEUTICS" |
| Goods and Services | Regulatory compliance consultancy services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acid, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, nucleic acid therapeutics as pharmaceutical preparations, and synthetic chemistry process technology for designing and synthesizing lipid nanoparticles |
| Goods and Services | Pharmaceutical preparations, namely, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics as pharmaceutical preparations; pharmaceutical preparations comprised of nucleic acids, namely, messenger RNA and lipid nanoparticles for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders; pharmaceutical preparations, namely, vaccines for human use for treating cancer, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders, genetic disorders, allergy; pharmaceutical preparations for gene silencing, for gene editing, for antibody therapeutics, for protein replacement therapeutics, and for nucleic acid therapeutics, for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders |
| Goods and Services | Research, development, and evaluation services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, nucleic acid therapeutics as pharmaceutical preparations, and synthetic chemistry process technology for designing and synthesizing lipid nanoparticles; synthetic chemistry services, namely, design, synthesis, analysis, evaluation, and biophysical characterization of lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, and lipid nanoparticles; preclinical study services, namely, conducting scientific feasibility studies, namely, pharmacodynamic and pharmacokinetic studies, scientific feasibility studies as to the human safety and tolerability studies regarding clinical pathology and histopathology, immune response characterization studies, and bioanalytical services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, and nucleic acid therapeutics as pharmaceutical preparations; scientific clinical research services, in the fields of chemical molecular analysis, pharmaceutical product optimization, and conducting clinical trial services for others in the field of pharmaceuticals; research and development of new formulation products for others, namely, vaccines and nucleic acid therapeutics; research and development for others in the fields of new pharmaceuticals, medical therapies, vaccines, gene therapies, drug delivery agents, and nucleic acid therapeutics for others; project management services for scientific research and development programs in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, nucleic acid therapeutics as pharmaceutical preparations, and synthetic chemistry process technology for designing and synthesizing lipid nanoparticles; consultancy services in the fields of scientific research and development of pharmaceuticals, medical therapies for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders and allergies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, nucleic acid therapeutics as pharmaceutical preparations, and synthetic chemistry process technology for designing and synthesizing lipid nanoparticles. |
| Goods and Services | Nucleic acids, namely, messenger RNA, for scientific purposes, research laboratory use |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, May 30, 2023 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, May 30, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, May 30, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, May 30, 2023 |
| Primary Code | 045 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Acuitas Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Vancouver, B.C. V6T1Z3 CA |
| Event Date | Event Description |
| Thursday, May 4, 2023 | NEW APPLICATION ENTERED |
| Tuesday, May 30, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, January 26, 2024 | ASSIGNED TO EXAMINER |
| Friday, January 26, 2024 | NON-FINAL ACTION WRITTEN |
| Friday, January 26, 2024 | NON-FINAL ACTION E-MAILED |
| Friday, January 26, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, April 16, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, April 16, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, April 16, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Sunday, May 12, 2024 | SUSPENSION LETTER WRITTEN |
| Sunday, May 12, 2024 | LETTER OF SUSPENSION E-MAILED |
| Sunday, May 12, 2024 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Thursday, July 18, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, July 18, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, July 18, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, July 18, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, July 18, 2024 | SUSPENSION LETTER WRITTEN |
| Thursday, July 18, 2024 | LETTER OF SUSPENSION E-MAILED |
| Thursday, July 18, 2024 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Friday, October 18, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Friday, October 18, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Friday, October 18, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, December 17, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, December 17, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, December 17, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, December 17, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, December 17, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Thursday, January 16, 2025 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Tuesday, July 15, 2025 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Tuesday, January 6, 2026 | ASSIGNED TO EXAMINER |
| Friday, January 16, 2026 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Wednesday, April 22, 2026 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Monday, April 27, 2026 | SUSPENSION INQUIRY WRITTEN |
| Monday, April 27, 2026 | INQUIRY TO SUSPENSION E-MAILED |
| Monday, April 27, 2026 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Friday, May 8, 2026 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Friday, May 8, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, May 15, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, June 12, 2026 | NON-FINAL ACTION WRITTEN |
| Friday, June 12, 2026 | NON-FINAL ACTION E-MAILED |
| Friday, June 12, 2026 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, June 16, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, June 16, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, June 16, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, June 24, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |